The safer management of controlled drugs 2025 highlights the Care Quality Commission’s oversight activity under the Controlled Drugs (Supervision of Management and Use) Regulations 2013. Private prescribing of unlicensed schedule 2 cannabis products rose by 134%, from 356,335 items 1 April 2023-31 March 2024 to 833,525 items 1 April 2024-31 March 2025.


